Poll: Vote on the Top Lung, GU Cancer Abstracts to Watch at ESMO 2025

The countdown to the 2025 ESMO Congress in Berlin, Germany has officially begun, and anticipation is already building across the oncology community. At this year’s meeting, the program again features presentations set to deliver potentially practice-changing data and key information for the management of various oncologic malignancies,

To capture the pulse of the field and prepare ahead of the meeting, we are inviting medical, academic, and community oncologists to take part in a series of polls, highlighting some of the most highly anticipated late-breaking abstracts (LBAs) and thematic areas.

This week, we’re taking a look at some of the key presentations and educational sessions surrounding the world of lung cancer and genitourinary (GU) cancers.

Your input will help spotlight the questions and innovations your peers are most eager to see addressed in Berlin. Polls are now live on X and LinkedIn, with voting open through Thursday, September 25. Please follow the links below to vote.

What Are the Top Abstracts to Watch in Lung Cancer at the 2025 ESMO Congress?

Lung cancer continues to dominate the global oncology conversation, with multiple LBAs poised to potentially shift treatment paradigms in both early-stage and advanced settings. Additionally, education sessions will highlight some of the key topics and debates currently at the center of the lung cancer space.

Poll 1: Which lung cancer abstracts are you most anticipating at ESMO 2025?

• LBA72 - NorthStar: A Phase II Randomized Study of Osimertinib (OSI) With or Without Local Consolidative Therapy (LCT) for Metastatic EGFR-Mutant Non-Small Cell Lung Cancer (NSCLC)
• LBA69 – SKYSCRAPER-03: Phase 3, open-label, randomised study of atezolizumab (atezo) + tiragolumab (tira) vs durvalumab (durva) in locally advanced, unresectable, stage III non-small cell lung cancer (NSCLC) after platinum-based concurrent chemoradiation (cCRT)
• LBA65 – Neoadjuvant durvalumab (D) + chemotherapy (CT) followed by either surgery (Sx) and adjuvant D or CRT and consolidation D in patients (pts) with resectable or borderline resectable stage IIB–IIIB NSCLC: interim analysis (IA) of the phase 2 MDT-BRIDGE study
• LBA74 – Zongertinib as first-line treatment in patients with advanced HER2-mutant NSCLC: Beamion LUNG 1

Poll 2: Which lung cancer themes are you most interested in seeing during ESMO 2025?

• Targeting Actionable Alterations
• Antibody–Drug Conjugates (ADCs)
• Trends in Small Cell Lung Cancer
• Defining Resectability in Lung Cancer

What Are the Top Abstracts to Watch in GU Oncology at the 2025 ESMO Congress?

Breakthroughs in GU oncology will be equally prominent on at ESMO in 2025, with LBA data expected across bladder cancer, prostate cancer, and renal cell carcinoma (RCC).

Poll 3: Which GU cancer abstract are you most anticipating at ESMO 2025?

• LBA96: First-line Pembrolizumab-based Regimens for Advanced Clear Cell Renal Cell Carcinoma: KEYMAKER-U03 Substudy 03A
• LBA107: ALBAN: A phase 3, randomized, open-label, international study of intravenous (iv) atezolizumab and intravesical Bacillus Calmette-Guérin (BCG) vs BCG alone in BCG-naïve high-risk, non-muscle-invasive bladder cancer (NMIBC)
• LBA86: Randomised phase 3 trial of androgen deprivation therapy (ADT) with radiation therapy with or without enzalutamide for high risk, clinically localised prostate cancer: ENZARAD (ANZUP 1303)
• LBA93: First results from RAMPART: An international phase 3 randomised-controlled trial of adjuvant durvalumab monotherapy or combined with tremelimumab for resected primary renal cell carcinoma (RCC) led by MRC CTU at UCL

Poll 4: Which GU cancer specialty are you most interested in learning more about during ESMO 2025?

• RCC
• Prostate Cancer
• Bladder Cancer

By voting, you’ll help highlight the abstracts and topics most relevant to the day-to-day realities of oncology practice. In the coming weeks, be on the lookout for additional polls covering the key abstracts and topics being presented in breast cancer, gastrointestinal cancer, gynecologic cancer, and hematologic oncology.